Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Joost van der Hoek"'
Autor:
Edwin Goedhart, Patrick Krastman, Afke H Brandenburg, Hendrik Gremmels, Marc Bonten, Beatrice Winkel, Emma Schram, Sylvia Debast, Rob Schuurman, Annemarie Wensing, Marije Hofstra, Tim Baijens, Marjan J Bruins, Bas Bulder, Wouter ten Cate, Juliete Djapo Tiani, Joost van der Hoek, Jannes Hornstra, Simon Knops, Maurine Leversteijn van Hall, Prabath Lodewijks, Frank Nab, Ron Peters, Mineke Vegter, Wart van Zoest
Publikováno v:
BMJ Open, Vol 11, Iss 10 (2021)
Background Antigen-based point-of-care tests for identification of SARS-CoV-2 may markedly enhance effectiveness of population-based controlling strategies. Previous studies have demonstrated >70% sensitivity and high specificity compared with revers
Externí odkaz:
https://doaj.org/article/1000e9ca62fc429381031b97ce4b3cec
Autor:
Ian Lewis, Gisbert Weckbecker, Herbert A. Schmid, Steven W.J. Lamberts, Viktor Boerlin, Joost van der Hoek, Günter Bovermann, Lukas Oberer, Janos Pless, Nagarajan Chandramouli, Wilfried Bauer, Rainer Albert, Christian Bruns
Publikováno v:
CHIMIA, Vol 58, Iss 4 (2004)
A rational drug design approach involving transposition of functional groups from SRIF into a reduced size cyclohexapeptide template has led to the discovery of SOM230, a novel, stable cyclohexapeptide somatostatin mimic which exhibits unique high af
Externí odkaz:
https://doaj.org/article/d902474928ed4ac9b119a949dab0d176
Publikováno v:
European Journal of Endocrinology, 156, S45-S51. Bioscientifica Ltd
The patho-physiological role of somatostatin receptor subtypes (sst) in neuro endocrine diseases has gained enhanced scientific interest in the past few years. The development of novel somatotropin-release inhibiting factor analogs, both sst-specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::049f7715d7ba255cfec81756a213df48
https://doi.org/10.1530/eje.1.02350
https://doi.org/10.1530/eje.1.02350
Publikováno v:
The Endocrinologist. 15:377-383
The clinical introduction of the long acting somatostatin (SS) analogs in the early 1980s added a new dimension to the treatment of acromegaly. Octreotide and lanreotide form a safe and effective medical therapeutic modality for acromegaly, mimicking
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1caa38c417da1cc07a87478dfd897e61
https://doi.org/10.1097/01.ten.0000186469.98034.9b
https://doi.org/10.1097/01.ten.0000186469.98034.9b
Autor:
Tillmann Krahnke, Aart-Jan van der Lelij, Kwai W. Poon, Steven W. J. Lamberts, P. Uitterlinden, Viktor Boerlin, Joost van der Hoek, Wouter W. de Herder, Richard A Feelders, Ian Lewis, Leo J. Hofland
Publikováno v:
Clinical Endocrinology, 63, 176-184. Wiley-Blackwell Publishing Ltd
Summary Objective Recently, our first clinical study with the novel multiligand somatostatin (SRIF) analogue SOM230 in acromegalic patients showed that SOM230, due to its beneficial inhibitory effects on GH levels compared with octreotide (OCT), migh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f14ea13788096bbcf33d9992b37eb169
https://doi.org/10.1111/j.1365-2265.2005.02322.x
https://doi.org/10.1111/j.1365-2265.2005.02322.x
Autor:
Joost van der Hoek, Jerry Nedelman, Peiming Ma, Ly‐Le Tran, Yanfeng Wang, Steven W. J. Lamberts, Horst F. Schran
Publikováno v:
Clinical Pharmacology & Therapeutics. 78:69-80
Objective Acromegaly is a serious hormonal disorder resulting from a pituitary adenoma causing excess growth hormone (GH) production. Somatostatin analogs such as octreotide have been the medical treatment of choice. SOM230, a novel somatostatin anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5f604d584b2d82eb0a5ef7161f9450b
https://doi.org/10.1016/j.clpt.2005.04.003
https://doi.org/10.1016/j.clpt.2005.04.003
Autor:
Diana Sprij-Mooij, Joost van der Hoek, Marlijn Waaijers, Leo J. Hofland, Steven W. J. Lamberts, Maarten O. van Aken, Wouter W. de Herder, Gisbert Weckbecker, Peter M. van Koetsveld, Christian Bruns, Richard A Feelders, Albert Beckers
Publikováno v:
European Journal of Endocrinology, 152(4), 645-654. Bioscientifica Ltd
Objective: Currently, there is no effective medical treatment for patients with pituitary-dependent Cushing’s disease. A novel somatostatin (SS) analogue, named SOM230, with high binding affinity to SS receptor subtypes sst1, sst2, sst3 and sst5 wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1824eb0e0d8a844fbd265502b1f0ea9f
https://doi.org/10.1530/eje.1.01876
https://doi.org/10.1530/eje.1.01876
Autor:
Leo J. Hofland, Gisbert Weckbecker, Aart-Jan van der Lely, Richard A Feelders, Marlijn Waaijers, Wouter W. de Herder, Peter M. van Koetsveld, Steven W. J. Lamberts, Diana Sprij-Mooij, Christian Bruns, Joost van der Hoek, Albert Beckers
Publikováno v:
Journal of Clinical Endocrinology and Metabolism, 89(4), 1577-1585. Endocrine Society
To determine the inhibitory profile of the novel somatostatin (SRIF) analog SOM230 with broad SRIF receptor binding, we compared the in vitro effects of SOM230, octreotide (OCT), and SRIF-14 on hormone release by cultures of different types of secret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27cd472a19986f8557daad1f6be2a17a
https://hdl.handle.net/1765/55379
https://hdl.handle.net/1765/55379
Autor:
Tillmann Krahnke, Steven W. J. Lamberts, Kwai W. Poon, Joost van der Hoek, Leo J. Hofland, Ian Lewis, Wouter W. de Herder, Christian Bruns, Gisbert Weckbecker, Aart-Jan van der Lely, Richard A Feelders, Viktor Boerlin, P. Uitterlinden
Publikováno v:
Journal of Clinical Endocrinology and Metabolism, 89(2), 638-645. Endocrine Society
Treatment with the somatostatin receptor (sst) subtype 2 predominant analogs octreotide and lanreotide induces clinical and biochemical cure in approximately 65% of acromegalic patients. GH-secreting pituitary adenomas, which are not controlled, also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b04ea8f466a51f9edf37a893a3eef0f
https://doi.org/10.1210/jc.2003-031052
https://doi.org/10.1210/jc.2003-031052
Publikováno v:
Expert Opinion on Investigational Drugs, 19(3), 385-399. Taylor & Francis Ltd
Importance of the field: In recent years, scientific work has been intensified to unravel new (patho-) physiological insights, particularly regarding the functional role of somatostatin (SRIF) receptor subtype 5 (sst) and the development of novel sst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe5e22652df3dd4601c9c39399a4c6da
https://pubmed.ncbi.nlm.nih.gov/20151855
https://pubmed.ncbi.nlm.nih.gov/20151855